Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1563563

	registered interest
	date	20/12/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Healthcare Travel Costs Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much of the funding to deliver the NHS Healthcare Travel Cost Scheme has been distributed to NHS trusts in each of the last 10 years.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	114699
	answer	answer is ministerial correction date of answer 24/01/2023 answer text <p>The information on funding distributed to National Health Service trusts to deliver the NHS Healthcare Travel Cost Scheme (HTCS) is not held centrally as funding is included within NHS Trusts’ baselines. No central monitoring is undertaken on who is in receipt of funds allocated through HTCS, or on how the money is spent. The scheme is administered by the NHS locally.</p><p>As part of its review into non-emergency patient transport services (NEPTS), including HTCS, NHS England has developed a National Minimum Data Set to monitor provision of NEPTS, including elements of HTCS, at integrated care system (ICS) level.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 114700 114701 question first answered 24/01/2023 12:05:15 answering member 4423 label Biography information for Will Quince
	tabling member	4450 label Biography information for Luke Hall

1563564

	registered interest
	date	20/12/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Healthcare Travel Costs Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information the Government requires NHS Trusts to publish under the NHS Healthcare Travel Cost Scheme.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	114700
	answer	answer is ministerial correction date of answer 24/01/2023 answer text <p>The information on funding distributed to National Health Service trusts to deliver the NHS Healthcare Travel Cost Scheme (HTCS) is not held centrally as funding is included within NHS Trusts’ baselines. No central monitoring is undertaken on who is in receipt of funds allocated through HTCS, or on how the money is spent. The scheme is administered by the NHS locally.</p><p>As part of its review into non-emergency patient transport services (NEPTS), including HTCS, NHS England has developed a National Minimum Data Set to monitor provision of NEPTS, including elements of HTCS, at integrated care system (ICS) level.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 114699 114701 question first answered 24/01/2023 12:05:15 answering member 4423 label Biography information for Will Quince
	tabling member	4450 label Biography information for Luke Hall

1563565

	registered interest
	date	20/12/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Healthcare Travel Costs Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what monitoring his Department carries out of who is in receipt of funds allocated through the NHS Healthcare Travel Cost Scheme, and what oversight he has of how this money is spent.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	114701
	answer	answer is ministerial correction date of answer 24/01/2023 answer text <p>The information on funding distributed to National Health Service trusts to deliver the NHS Healthcare Travel Cost Scheme (HTCS) is not held centrally as funding is included within NHS Trusts’ baselines. No central monitoring is undertaken on who is in receipt of funds allocated through HTCS, or on how the money is spent. The scheme is administered by the NHS locally.</p><p>As part of its review into non-emergency patient transport services (NEPTS), including HTCS, NHS England has developed a National Minimum Data Set to monitor provision of NEPTS, including elements of HTCS, at integrated care system (ICS) level.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 114699 114700 question first answered 24/01/2023 12:05:15 answering member 4423 label Biography information for Will Quince
	tabling member	4450 label Biography information for Luke Hall

1537799

	registered interest
	date	31/10/2022
	answering body	Treasury
	answering dept id	14
	answering dept short name	Treasury
	answering dept sort name	Treasury
	hansard heading	Parental Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Chancellor of the Exchequer, what steps the Government is taking to reduce the anticipated 18 months’ lead time that HMRC require, in order to implement paid neonatal leave following Royal Assent for the Neonatal Care (Leave and Pay) Bill.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	74755
	answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>The Government is committed to implementing entitlement to Neonatal Leave and Pay as soon as possible. HMRC cannot begin delivery until the Neonatal Care (Leave and Pay) Bill has Royal Assent. Provisions in the Bill bring this new statutory payment within scope of HMRC’s legal functions, giving it the authority to incur costs.</p><p> </p>HMRC will need to make changes to their IT systems for the administration, payment and reporting of Neonatal Pay, as well as supporting customers with a calculator, a new suite of online forms and updated guidance. HMRC also need to draw up and publish requirements for external developers, who will need to build Neonatal Leave and Pay into their payroll software products so that employers can administer Neonatal Leave and Pay through payroll. HMRC is working closely with BEIS to establish exact delivery timelines on the basis that Royal Assent is expected in Spring 2023. answering member constituency Louth and Horncastle answering member printed Victoria Atkins question first answered 08/11/2022 17:53:37 answering member 4399 label Biography information for Victoria Atkins
	tabling member	4450 label Biography information for Luke Hall

860725

	registered interest
	date	12/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress has been made on negotiations between NHS England and Vertex Pharmaceuticals on access to the drug Orkambi for people with cystic fibrosis.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	132082
	answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>NHS England is currently in discussion with Vertex about its range of drugs for treating cystic fibrosis, including the drug Orkambi. NHS England will continue to support discussions with pharmaceutical companies that aim to provide clinically effective medicines to patients at a level that is cost-effective, in line with standard National Institute for Health and Care Excellence practice for assessing new drugs before they are introduced into the National Health Service.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 16:40:41 answering member 4067 label Biography information for Steve Brine
	tabling member	4450 label Biography information for Luke Hall

942538

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	164468
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:09:26 answering member 4067 label Biography information for Steve Brine
	tabling member	4450 label Biography information for Luke Hall

942539

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	164469
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>It is a key commitment of this Government to ensure that people with comparatively rarer conditions, like cystic fibrosis, get the same quality, safety and efficacy in medicines as those who have more common conditions.</p><p> </p><p>However, it is also necessary that Vertex prices Orkambi fairly and responsibly. That is why we must go through the right process with Vertex and NHS England, not the Government, working together to secure the best outcome for patients. NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:10:54 answering member 4067 label Biography information for Steve Brine
	tabling member	4450 label Biography information for Luke Hall

942540

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether a date has been set for the next meeting between NHS England and Vertex to discuss access to the drug Orkambi.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	164470
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>We are informed by NHS England that at the last meeting on 4 July, it was agreed that both parties would take time to reflect before a further meeting was arranged. NHS England has subsequently made a substantially increased proposal to Vertex and has offered to meet to discuss and clarify any aspects as required by the company.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:48:08 answering member 4067 label Biography information for Steve Brine
	tabling member	4450 label Biography information for Luke Hall

942541

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his Department's policy is on Vertex (a) waiving its confidentiality clause on the negotiations around NHS access to the drug Orkambi and (b) disclosing details of its offer to NHS England.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	164471
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>It is not in the Department’s gift to impose any requirement upon Vertex to waive its confidentiality clause or to disclose details of any offer in the negotiations around National Health Service access to the drug Orkambi. However, Ministers at the department have publicly urged Vertex to consider the offer made by NHS England and to waive confidentiality so that we can all see, in the interests of transparency, the kind of prices it is seeking to charge the NHS.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:43:39 answering member 4067 label Biography information for Steve Brine
	tabling member	4450 label Biography information for Luke Hall

969030

	registered interest
	date	06/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	171383
	answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171384 question first answered 14/09/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
	tabling member	4450 label Biography information for Luke Hall